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Abstract
Background: Patients and clinicians expect patient decision aids to be based on the best available research
evidence. Since 2005, this expectation has translated into a quality dimension of the International Patient Decision
Aid Standards.
Methods: We reviewed the 2005 standards and the available literature on the evidence base of decision aids as
well as searched for parallel activities in which evidence is brought to bear to inform clinical decisions. In
conducting this work, we noted emerging and research issues that require attention and may inform this quality
dimension in the future.
Results: This dimension requires patient decision aids to be based on research evidence about the relevant options
and the nature and likelihood of their effect on outcomes that matter to patients. The synthesis of evidence should be
comprehensive and up-to-date, and the evidence itself subject to critical appraisal. Ethical (informed patient choice),
quality-of-care (patient-centered care), and scientific (evidence-based medicine) arguments justify this requirement.
Empirical evidence suggests that over two thirds of available decision aids are based on high-quality evidence
syntheses. Emerging issues identified include the duties of developers regarding the conduct of systematic reviews, the
impact of comparative effectiveness research, their link with guidelines based on the same evidence, and how to
present the developers’ confidence in the estimates to the end-users. Systematic application of the GRADE system,
common in contemporary practice guideline development, could enhance satisfaction of this dimension.
Conclusions: While theoretical and practical issues remained to be addressed, high-quality patient decision aids
should adhere to this dimension requiring they be based on comprehensive and up-to-date summaries of critically
appraised evidence.
Background
The original 2005 International Patient Decision Aid
Standards (IPDAS) formulation included a key quality
dimension then labeled as “basing information on up-
to-date scientific evidence”. This dimension reflected the
Standards panel’s belief that these tools should advance
evidence-based practice. Since 2005, much work has
taken place that advances the use of research evidence
to develop tools that support clinical decision making,
requiring a review and update in the formulation of this
quality dimension. For this iteration, we put forward a
more detailed description of this dimension. We now
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on comprehensive, critically appraised, and up-to-date
syntheses of the scientific evidence.
In this manuscript, we present a detailed description
of this quality dimension, the theoretical and empirical
justification for evaluating patient decision aids accord-
ing to this dimension, and discuss the emerging issues
and research areas for consideration and discussion
identified during this endeavor.
The dimension and its features
IPDAS requires patient decision aids to base their infor-
mation on comprehensive, critically appraised, and up-to-
date syntheses of the scientific evidence. This refers to the
information about the various relevant options, and about
the descriptions and likelihoods of those options’ effects
on the outcomes of most importance to patients.
The term “scientific evidence” refers to a body of empiri-
cal observations about the options and their consequences.
These observations should be made with some degree of
protection against systematic and random error.
By “comprehensive”, we do not mean the scope and
range of the information presented in the decision aid.
Instead, in defining this quality dimension, “comprehen-
sive” refers to the extent to which decision aid developers
have thoroughly considered all the pertinent scientific
evidence addressing each aspect that they chose to pre-
sent in their decision aid.
The requirement that the evidence be “critically
appraised” means that decision aid developers will use
evidence derived from systematic reviews that: a) avoid
selection bias (i.e., avoid introducing bias into the review
in the selection of studies to include); b) carefully and
reproducibly assess the quality of the incorporated
reviewed studies (i.e., the studies’ protection from error
and bias); c) summarize the estimated pertinent effects
(ideally quantitatively in a meta-analysis); d) indicate the
extent to which these estimates are trustworthy; and e)
assess the extent to which selective reporting and publi-
cation bias may corrupt the body of evidence. Develo-
pers must present this synthesized evidence in the
decision aid itself in a way such that it a) conveys that
the aid is offering the “best available” synthesized infor-
mation, and b) indicates—using symbols, numbers, or
phrases—the degree of confidence attributed to that
information, given the quality of the scientific evidence
upon which it is based.
The dates when the relevant systematic reviews were
searched for, compiled, critically appraised, and synthe-
sized by decision aid developers should be reported and
should be sufficiently recent given the pace of progress in
the particular field to be considered “up-to-date”. This
implies that decision aid developers should develop a
sense of the speed with which evidence that matters
accrues in their area of work, and implement an update
policy. Developers should report a version date, and,
when pertinent, a “better by” or “expiration date” to com-
municate to decision aid users about the speed of evi-
dence accrual in the field and the optimal timing of
future updates.
Theoretical justification for evaluating patient
decision aids on this quality dimension
As we described above, clinicians and patients expect
patient decision aids to be evidence-based tools. This
alone could justify this dimension (and indeed it did in
its 2005 formulation). Here, we push the rationale further
a) by connecting it with three fundamental arguments –
an ethical argument, a quality-of-care argument, and a
scientific argument – that are central to contemporary
clinical care, and b) by describing recent advances in the
rating of the degree of confidence in the estimates of
effect justified by the state of the available scientific
evidence.
Supporting arguments
Three fundamental arguments central to contemporary
clinical care justify the IPDAS’s evidence dimension.
Informed Patient Choice
One key principle driving the development of patient deci-
sion aids is the ethical argument for informing patients
about their health care choices. Respect for patient auton-
omy is a governing principle of medical ethics [1], and is
generally understood to refer to an individual’s ability to
make and carry out informed health care decisions based
on unbiased and thoughtful deliberation. The American
Board of Internal Medicine, the American College of
Physicians, and the European Federation of Internal Medi-
cine state in their charter on medical professionalism that
“physicians must be honest with their patients…and
ensure that patients are completely and honestly informed
before the patient has consented to treatment and after
treatment has occurred.”[2] To be “completely and hon-
estly informed” so that autonomy can be exercised
requires access to unbiased information that is based on a
high-quality synthesis of the available evidence that is rele-
vant to the patient’s clinical situation and that acknowl-
edges where uncertainty exists because of the quality or
quantity of that evidence. When used as part of a shared
decision making process, high-quality patient decision aids
that are based on the best available clinical evidence sup-
port clinicians in fulfilling their ethical obligation to pro-
mote autonomy by ensuring that patients are fully
informed about their health care choices.
Patient-Centered Care
The growing emphasis on patient-centered care is
another driving force behind the development of patient
decision aids. Principles of patient-centered care require
that patients actively participate in decision making and
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be provided with the information and support they need
to make informed choices. Work by the Picker Institute
and others has identified respect for the patient’s values
and preferences, as well as access to clear, high-quality
information and education to be among the important
characteristics of patient-centered care [3]. Patient deci-
sion aids support the practice of patient-centered care
by ensuring that patients’ preferences are informed and
based on accurate expectations; this requires, in turn,
that the tools be based in high-quality evidence that,
when possible, is relevant to patients’ individual risk
profiles.
Evidence-Based Medicine
Over the last 20 years, evidence-based medicine (EBM)
has strongly influenced the practice of medicine [4] as it
has required use of the best available evidence alongside
clinical expertise to formulate recommendations to
patients that are pertinent to their context and sensitive
to their values and preferences. To this extent, EBM fol-
lows two principles.
The first principle recognizes that not all observations
and experiments are similarly protected from random
and systematic error. The degree of protection from
error offers confidence in the estimates of effect. There-
fore, in the interests of fostering EBM, the information
presented in patients’ decision aids should include not
only evidence-based estimates of the effects of the var-
ious relevant options, but also an indication of the
extent to which this evidence is protected from error
(i.e., we can have confidence in the estimates of effect).
The second principle holds that the evidence alone is
never sufficient to fully inform a clinical decision. The
evidence will be considered during the transactions
between the treating clinician with a particular level of
expertise and the patient with unique goals, values, and
preferences; furthermore, the evidence will be applied in
a particular biological, psychological, and sociocultural
context. Therefore, in the interests of fostering EBM,
the information presented in patients’ decision aids
needs to be directly applicable to the patients and prac-
titioners using the decision aid, and tailored to indivi-
dual patients’ characteristics.
Ethical (informed patient choice), quality (patient-
centered care), and scientific (evidence-based medi-
cine) justifications make it imperative that decision
aids be based on comprehensive, critically appraised,
and up-to-date scientific evidence.
Rating the degree of confidence in the estimates of effect
Decision aid developers may want to include informa-
tion in their tool that is based on different forms of evi-
dence. Natural history and prognostic information, for
instance, often requires the developer to use large and
long observational studies. Adverse effects, particularly
those that are rare, may be better characterized in case
reports, and their linkage to exposures ascertained
through case-control studies. This notion of a hierarchy
of evidence has received much attention and has
resulted in an emerging consensus in the practice guide-
lines movement about how to assess the confidence in
the estimates of effect from the body of pertinent evi-
dence: the GRADE approach. While we will now focus
on this approach, we recognize that other approaches to
grading the evidence exist, but they have substantial
shortcomings that this method obviates. Furthermore,
consistency in rating evidence from guideline to decision
aid may facilitate the development of decision aids in
conjunction with clinical practice guidelines efforts.
The GRADE Approach
GRADE (Grading of Recommendations Assessment,
Development and Evaluation) is the most comprehen-
sive approach developed for the purposes of formulating
clinical practice guidelines[5]. It could be particularly
helpful for decision aid developers, as an approach to
explaining to patients the extent to which one can have
confidence in the pertinent estimates of an option’s
effects.
We will summarize the GRADE approach to grading
evidence of effectiveness here, but developers should
review the extensive published guidance (http://www.
gradeworkinggroup.org).
A key feature of this approach is that the assessment
of quality applies to the body of evidence (not just to
the individual study). This includes: a) the likelihood of
bias (from the absence of protective features such as
concealed randomization, blinding of pertinent groups,
and analysis of participants as randomized)[6]; b) the
likelihood of reporting or publication bias [7]; c) incon-
sistency in results across studies [8]; d) any imprecision
in the estimates of effect (e.g., wide confidence intervals)
[9]; and d) the degree of indirectness, in which the
results do not directly apply to the pertinent patients,
the comparisons are inadequate, or the studies measure
a surrogate of limited validity [10].
Randomized trials often provide high confidence in
effect estimates. The task is to identify limitations that
would reduce our confidence in those estimates. Obser-
vational studies often provide low confidence in effect
estimates, limitations further reduce that confidence, but
some features, such as strong evidence of a dose-
response relationship or evidence of a very large effect
[11], increase our confidence. Importantly, this confi-
dence differs by outcome such that, for example, we may
have more confidence in the effects of an intervention on
patient important benefits while having low confidence
in its effects on harms.
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Empirical evidence regarding this quality
dimension
To evaluate the current practice of including evidence in
decision aids, we examined the Ottawa Decision Aid
Inventory (http://decisionaid.ohri.ca/azinvent.php). Out
of 257 decision aids included in the inventory, 134 pro-
vided references to scientific evidence used, when they
were last updated (n = 135), and whether they were
available on the Internet (n = 134). In a random sample
of those decision aids (n = 20), stratified to correct for
differences between providers, ten aids used a high qual-
ity systematic review/meta-analysis (AMSTAR score [12]
ranging from 2 to 11 on a scale of 1-11), and five aids
were based on practice guidelines (AGREE II score [13]
ranging from 1 to 6 on a scale of 1-7). Two decision
aids used data from multiple sources of original
research, whereas two used only a narrative review or
an expert’s opinion or a single piece of original research
as the sources for evidence. Four decision aids did not
explicitly cite, hence we could not locate and evaluate,
the evidence they used. One of the 20 aids explicitly sta-
ted an expiration date and an update policy, whereas
eight refer to a policy statement of the complete con-
tents on the provider website (as part of a site notice on
the website, but not as part of the aid itself). Three used
the GRADE system in their presentation to clarify the
quality of the evidence to the user.
Discussion
Linking the quality of a patient decision aid to the quality
of the process by which developers comprehensively iden-
tified, synthesized, and appraised up-to-date evidence is a
key dimension represented in the IPDAS. Furthermore,
the little empirical evidence available suggests much room
for improvement. The risk with standards is to suggest
that no uncertainties remain or that innovation has stalled.
Neither is true with relation to this topic. In working
through these issues, the authors identified the following
emerging topics and research areas for discussion. The
process by which these areas were identified and are high-
lighted here does not pretend to be systematic or all-
encompassing, but rather serves as a starting point for a
community-wide conversation.
How might developers decide what evidence used to
inform a decision might be pertinent to the patients who
are the intended audience of the tool?
The extent to which evidence is pertinent is subject to
much judgment. Users may end up having low confi-
dence in estimates of subgroup effects (e.g., subgroup
effects that cannot be confirmed or are very imprecise),
such that it is sometimes advisable to use estimates from
the general population [14]. The challenge of applying
evidence from somewhat different patients, interventions,
or outcomes to the situation of interest falls under the
general rubric of indirectness [10]. The degree with
which these differences are likely to undermine the
applicability of the evidence—that is, the extent of indir-
ectness—reduces the confidence that the estimates of
effect are correct, and this could be reflected in the deci-
sion aid. Efforts to improve the volume and quality of
comparative effectiveness research [15] may enhance the
evidence base for decision aids, because this research
requires direct comparisons that matter to clinical stake-
holders – that is, measuring the effect of interventions on
outcomes of importance to patients.
How often should systematic reviews be updated?
The frequency with which systematic reviews should be
updated – and, by extension, the products derived from
these reviews – is still subject to research. A comprehen-
sive technical review commissioned by the Agency for
Healthcare Research and Quality and published in 2007
[16] found that the median time for the emergence of a
signal that a review should be updated (e.g., substantial
new evidence of effectiveness or harm, new alternatives,
revelations about the nature of the old evidence) was 5.5
years; yet about 25% of the reviews could benefit from
updating within 2 years of publication. The authors were
not able to identify predictors of more urgent review and
suggested yearly surveillance of systematic reviews.
How might we trust tailored estimates?
Decision aids often need to present absolute risk esti-
mates that relate to the individual characteristics of the
patient of interest. There is considerable uncertainty
about such baseline risks [17]. Prognostic calculators
offer the opportunity to tailor such risk estimates. Given
the importance of these estimates, decision aid develo-
pers must report which calculator they are using and
provide an assessment of its validity, a matter that often
requires independent evaluation from the population
from which the formula was derived, as well as compari-
sons with competing risk estimators [18].
How might developers communicate their confidence in
the estimates of effect?
Communicating the confidence that decision aid develo-
pers have in the estimates of the benefits and harms asso-
ciated with the selected options would help decision aid
users to make sense of the magnitude and trustworthiness
of the estimates. The communication of this confidence in
the evidence should be done in a way that is simple and
understandable, yet remains precise, without adding cogni-
tive burden on decision aid users.
There is limited empirical work on how to communi-
cate confidence in effect estimates to stakeholders in
general, let alone decision aid users. A systematic review
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of information in decision aids reported that very few
decision aid developers had addressed or incorporated
confidence in effect estimates in their tools [19]. The
ways by which these developers were representing this
concept varied greatly, from icons (i.e., bronze-gold
medals), to verbal labels (i.e., high, moderate, low), and
to numeric intervals, and these have yielded mixed
results [19].
The GRADE approach for guidelines offers a simple way
to report on confidence in effect estimates, using categori-
cal labels—for example, “very low”, “low”, “moderate”, and
“high” confidence. [20,21]. An obvious advantage gained
from using the same approach in guidelines and in deci-
sion aids to rate confidence in effect estimates is that deci-
sion aid developers could use the evidence supporting
current high-quality guidelines as their source for up-to-
date evidence.
Will linking information to evidence-based practice
guidelines foster decision aid uptake?
A key issue with decision aids is their underuse in prac-
tice, despite increasing evidence of their effectiveness
and surging policy support in some regions. Thus,
efforts to explicitly link their design and content to clin-
ical policy and workflow may facilitate their adoption.
This supports in part our approach of linking the devel-
opment and content of decision aids to state-of-the-art
approaches to the development and content of evi-
dence-based practice guidelines.
The “ideal” situation indicating the potential usefulness
of a patient decision aid is one in which there is evidence
producing high-confidence estimates linking options to
outcomes, but the options are closely matched, and the
choice of the “best” course of action will depend mostly
on the patient’s values and preferences. Guideline develo-
pers following GRADE usually will offer a weak or condi-
tional suggestion in those circumstances. A suggestion
based on high-confidence evidence would require the
incorporation of patient values and preferences for
implementation, that is, would benefit from a decision
aid. This linkage between guidelines and decision aids
may affect the development and uptake of decision aids.
Furthermore, implementation of the guidelines, for
example, in quality improvement efforts, could then be
linked to the implementation of decision aids for weak or
conditional suggestions.
What happens with patient decision aids that contradict
extant practice guidelines?
A key aspect worthy of surveillance is the fate of deci-
sion aids that have been developed based on the best
available evidence, but which disagree in their presenta-
tion with extant guidelines and with the quality-of-care
parameters derived from these guidelines. These
discrepancies can appear because decision aids may use
more recently updated summaries of evidence, or
because the recommendations apply to a different con-
text or resulted from panels with distorted values (e.g.,
due to pharmaceutical lobbying). In one example, this
apparent divergence led to difficulties in the use of the
decision aid and to its nonuse [22].
Will adherence to this dimension improve decision aid
use in practice?
Given that the uptake in practice of decision aids remains
limited, there is no strong evidence that decision aids sup-
ported by high quality and updated summaries of the body
of evidence would be more likely to be taken up in prac-
tice. It is plausible, however, that adherence to this domain
may create a reputation for high credibility that could
drive the uptake of decision aids. There is no a priori rea-
son to believe that the quality of the process of evidence
synthesis and its adaptation into evidence-based decision
aids will lead to better decision processes and outcomes.
Yet, basing their content on accurate rather than inaccu-
rate estimates may lead to better outcomes. These central
concerns, therefore, remain important research questions.
Conclusions
A key quality dimension for patient decision aids is how
developers identified, summarized, and used research evi-
dence to inform the content of these tools. Patients and
clinicians have the expectation that these tools will sup-
port evidence-based practice. Ethical, quality-of-care, and
scientific arguments justify making this an IPDAS stan-
dard. Empirical evidence suggests that there is much room
for improvement in developers’ adherence to this stan-
dard. Applying the methodological developments of the
GRADE working group to this task may help developers
enhance their adherence to this domain and thus the qual-
ity of their patient decision aids. It may also help position
the development of decision aids in the same development
stream as that of high quality clinical practice guidelines.
Yet, much room exists for research and innovation into
the processes that create patient decision aids based on
comprehensive and up-to-date syntheses of all the perti-
nent and critically appraised scientific evidence.
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